Several immunohistochemical studies have addressed the relationship between GPR30 and breast cancer outcome, but the results are inconsistent with the receptor conveying either better [42,43] or worse prognosis [15,16,44], or lacking any prognostic value [45] for breast cancer outcome. This evidence concerns the gene GPER1 and breast carcinoma.